SIGMAR1 Knockdown Enhances Oral Cancer Cell Chemosensitivity to Cisplatin via Decreased PD-L1 Expression
Emerging evidence suggests that aberrant expression levels of Sigma1 (SIGMAR1, also known as sigma-1 receptor) have been implicated in the progression of various diseases, including cancer. However, its significance in oral cancer (OC) has not been thoroughly explored. To advance in this field, the present study aimed to investigate the impact of SIGMAR1 knockdown in oral cancer cells. To do so, we included in this study our cohort of human OC samples and OC cell lines, which were utilized for experimental verification through several in vitro assays. Our findings revealed that SIGMAR1 overexpression was associated with poor survival rates and positively correlated with PD-L1 overexpression in human oral cancer samples. Furthermore, SIGMAR1 inhibition led to a decrease in PD-L1 expression and sensitized oral cancer cells to cisplatin treatment by enhancing apoptosis. These results suggest that SIGMAR1 knockdown may present a promising strategy worthy of further exploration in the management of oral cancer.
Citação
@online{pablo_shimaoka2024,
author = {Pablo Shimaoka , Chagas and Cristiana Bernadelli , Garcia
and Lucas Oliveira , Sousa and Silva, Gabriel, Da and Graziella
Ribeiro De , Sousa and Rodolfo Cabral , Marcelino and Matos, Leandro
Luongo, De and Luiz Paulo , Kowalski and Évila , Salles and Lei ,
Wang and Babak , Baban and Andréia Machado , Leopoldino},
title = {SIGMAR1 Knockdown Enhances Oral Cancer Cell Chemosensitivity
to Cisplatin via Decreased PD-L1 Expression},
volume = {25},
number = {22},
date = {2024-11-05},
doi = {10.3390/ijms252211856},
langid = {pt-BR},
abstract = {Emerging evidence suggests that aberrant expression levels
of Sigma1 (SIGMAR1, also known as sigma-1 receptor) have been
implicated in the progression of various diseases, including cancer.
However, its significance in oral cancer (OC) has not been
thoroughly explored. To advance in this field, the present study
aimed to investigate the impact of SIGMAR1 knockdown in oral cancer
cells. To do so, we included in this study our cohort of human OC
samples and OC cell lines, which were utilized for experimental
verification through several in vitro assays. Our findings revealed
that SIGMAR1 overexpression was associated with poor survival rates
and positively correlated with PD-L1 overexpression in human oral
cancer samples. Furthermore, SIGMAR1 inhibition led to a decrease in
PD-L1 expression and sensitized oral cancer cells to cisplatin
treatment by enhancing apoptosis. These results suggest that SIGMAR1
knockdown may present a promising strategy worthy of further
exploration in the management of oral cancer.}
}